ArticlePlant foods for human nutrition (Dordrecht, Netherlands)2026
Sargassum fusiforme-derived Exosome-like Nanoparticles Suppress TLR4/MyD88/NF-κB Pathway to Alleviate Colitis via Modulating Gut Microbiota.
Article in Plant foods for human nutrition (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Plant-derived exosome-like nanoparticles (PELNs) offer both prophylactic and therapeutic potential for ulcerative colitis (UC). Following the successful isolation of Sargassum fusiforme-derived exosome-like nanoparticles (SELNs), this study investigated the protective efficacy of SELNs in mitigating Citrobacter rodentium-induced colitis. SELNs administration exhibited prolonged gut retention and colon-targeting efficacy and significantly alleviated colitis symptoms, including body weight loss, colonic shortening, and histological damage, while promoting tight junction and MUC2 protein expression. SELNs suppressed the TLR4/MyD88/NF-κB cascade, a key inflammatory pathway, resulting in downregulated pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and upregulated anti-inflammatory cytokines (IL-10, IL-22), coupled with iNOS abrogation. Furthermore, SELNs modulated the gut microbiota compositon, especially increasing the abundance of Muribaculum intestinale, and promoted the production of short-chain fatty acids (SCFAs). Collectively, these findings suggest that SELNs possess significant promise as a functional food ingredient for colitis through intestinal homeostasis modulation and inflammatory pathway regulation. Given their natural source and potent anti‑inflammatory effects, SELNs hold good potential for commercialization as a novel nutraceutical for inflammatory bowel disease intervention.
Indexed as
Identifiers
41526538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.